PSG’s Perspective on AI in Healthcare and Pharmacy Benefits

Leveraging AI to Better Identify Fraud, Waste, and Abuse (FWA)

Key Points

• Responsible AI implementation brings clarity to pharmacy benefit strategy when it is trustworthy, explainable, and aligned with real-world clinical and regulatory environments.
• PSG’s attribute-driven AI model for FWA detection, built within Artemetrx, delivers interpretable risk scores grounded in clinical rigor without requiring PHI to train.
• Effective AI in healthcare requires local validation, ongoing monitoring, structured feedback loops, and strong governance.
• AI’s role in healthcare is not to replace human expertise but to meaningfully augment it with richer context and reliable intelligence.

Artificial intelligence is accelerating change across every major industry, and few sectors stand to benefit more than healthcare. At PSG, we’re observing this transformation and leaning into it with purpose and enthusiasm. AI is opening doors to possibilities that were simply not achievable even a few years ago, and the momentum is only growing. From advanced analytics to intelligent automation, AI is empowering organizations to make faster decisions, uncover hidden insights, and elevate the role of clinical expertise. In this article, we’ll outline how responsible AI use can support your pharmacy benefits strategy, how we’re leveraging AI to improve detection of FWA, and how to build more than just an algorithm to create AI that fits in the real world.

Responsible AI Use Enhances Pharmacy Benefit Strategy

The true strength of artificial intelligence within the pharmacy benefit and healthcare ecosystem lies not merely in the technology itself, but in its deliberate and responsible implementation. At PSG, we’re committed to delivering AI that works in the real world. This means AI that is trustworthy, explainable, and aligned with the complex regulatory, contractual, and clinical environments our clients operate in. Our excitement comes from knowing that AI, when built correctly, doesn’t add noise but instead brings clarity.

As we bring advanced AI capabilities into our products and services, we’re focused on solutions that enhance clinical reasoning, simplify decision‑making, and enable organizations to see around corners. We’re designing AI that is not only powerful but inherently practical to help clients anticipate risk, optimize performance, and take confident action with insights they can trace and trust. 

In short, AI isn’t just reshaping the healthcare landscape, it’s redefining what’s possible within it. And PSG is proud to be building the kind of responsible, high-impact AI that moves the industry forward.

A Market‑Ready, Attribute‑Based AI Approach to FWA

One example of how PSG is leveraging AI is through our new AI‑enabled, attribute‑driven method for identifying potential FWA. Built in our proprietary data and analytics platform, Artemetrx, our model identifies instances of FWA and assigns scores for a simple snapshot of your risk. The model is grounded in clinical rigor and optimized for healthcare data governance. It evaluates each claim through a structured set of risk indicators developed collaboratively with our team of pharmacists, clinicians, and FWA specialists.

These attributes assess patterns across areas such as:

• Prescriber behaviors
• Pharmacy dispensing trends
• Diagnosis and therapy alignment
• Member utilization profiles
• Cost and quantity dynamics

This design results in clearer, more interpretable outputs that not only show you the risk but also give you insight into why a claim triggers a risk signal. In doing so, it also helps reduce false positives and enables more targeted investigation. Additionally, this model does not require PHI to train it. These clinically-driven rules are applied universally, and they work without feeding sensitive patient data into a training process.

In short, this example demonstrates how we are using human expertise to build an effective tool that can evolve within a clinician-built framework rather than relying on an unguided black box.

Building AI That Fits the Real World

Successful AI adoption in healthcare depends on much more than just algorithms. It requires thoughtful workflow integration, user‑centered design, and strong governance. PSG ensures every AI initiative includes:

• Local validation before deployment confirms the model performs accurately by reviewing output with our clinical experts
• Ongoing monitoring and drift detection catches changes in data patterns early so outputs stay reliable over time
• Clear user interfaces and explanations make insights interpretable so teams can trust, defend, and act on them
• Structured feedback loops turn frontline user input into continuous improvement and fewer repeat issues
• Version control and controlled rollout processes prevent surprises by validating that changes are tracked, testable, and safely introduced

These guardrails are essential to maintaining trust and ensuring outputs enhance decision‑making rather than introducing risk. Our goal is not to create automation for automation’s sake, but rather for it to be a meaningful augmentation of human expertise.

Looking Ahead: The Future of AI in Healthcare and Pharmacy Benefits

AI is set to drive even deeper transformation across healthcare and pharmacy benefits, and PSG is energized by what’s ahead. As data ecosystems mature and workflows become more digital, AI will shift from simply informing decisions to truly enhancing them. We see a future where clinicians, analysts, and operational teams leverage AI tools that continuously surface insights, anticipate issues, and bring greater clarity to complex environments.

This evolution is not about replacing human expertise but strengthening it with richer context and reliable intelligence. To reach this future responsibly, AI must scale with transparency, strong governance, and clinical rigor.

The next chapter of AI in healthcare will reward organizations that are proactive, agile, and grounded. PSG is ready to help lead that chapter. AI is already a powerful partner in our ecosystem, and we believe the most exciting innovations are still ahead.

Share on: